

PUBLIC SUMMARY DOCUMENT

Product: Omnigon Eakin Dot
Applicant: Omnigon Pty Ltd
Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Omnigon, sought listing of the Eakin Dot two-piece closed pouch with mechanical coupling, in subgroup 5(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including three variants, was proposed at the unit price of \$1.564 with a maximum monthly quantity of 90 units.

2. Comparator

The applicant nominated Omnigon Welland Flair 2 (9995C) from its own range, which is currently listed in subgroup 5(a), as the comparator. This product is currently listed at the unit price of \$1.564 with a maximum monthly quantity of 90 units.

3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product is an alternative for users requiring a two-piece closed pouch with mechanical coupling. The product is a direct substitute for the comparator currently available in subgroup 5(a).

5. SPAP Comment

Clinical Analysis

The Panel noted that the closed bags are manufactured in three sizes; mini, standard and maxi to suit the requirements of the end users. The bags each have a bag-side coupling mechanism which provides mechanical attachment to the body-side coupling. All pouches have a single carbon, protected filter for the escape and deodorisation of gas.

Economic Analysis

Not undertaken.

Financial Analysis

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 5(a) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

6. SPAP Recommendation

The SPAP recommended that the Eakin Dot two-piece closed pouch, including three variants, be listed in subgroup 5(a) of the SAS Schedule at the benchmark unit price \$1.564, with a maximum monthly quantity of 90 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is

an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Omnigon agrees with SPAP's recommendation